In a memo, CEO Stéphane Bancel said the job cuts are needed to align the struggling vaccine maker’s cost structure with the ...

Merck’s Enflonsia is part of the company’s growing vaccine portfolio, which has become an increasingly important revenue segment alongside its oncology and other pharmaceutical divisions.

Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company announced that the US FDA approved ENFLONSIA™ (clesrovimab-cfor) for the prevention ...

Merck & Co., Inc. (NYSE:MRK) ranks among the best set-it-and-forget-it stocks to buy. On June 27, TD Cowen maintained its Hold rating and $100 price target on Merck & Co., Inc. (NYSE:MRK) after a ...

Merck (MRK) may be a storied pharmaceutical giant with a 134-year history, but it still has a lot of room to run. Merck is well-known for its cancer treatment Keytruda, vaccine leadership, and a ...

Merck said it plans to make the drug available in the U.S. ahead of the upcoming RSV season. Enflonsia joins a growing arsenal of tools to prevent RSV in infants.

Merck plans to make ENFLONSIA available for ordering by physicians and health care administrators in July 2025, with shipments to be delivered before the start of the 2025-2026 RSV season.

Merck plans to make ENFLONSIA available for ordering by physicians and health care administrators in July 2025, with shipments to be delivered before the start of the 2025-2026 RSV season.

Merck & Co., Inc. (NYSE:MRK) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 26, Merck & Co., Inc. (NYSE:MRK) announced that the Advisory Committee on Immunization Practices has ...

Advisory Committee on Immunization Practices (ACIP) recommendation expands respiratory syncytial virus (RSV) prevention options: Merck’s Enflonsia is now recommended for infants under eight months of ...

Merck plans to make Enflonsia available for physicians and healthcare administrators to order in July 2025. Shipments will be delivered before the start of the 2025-2026 RSV season.